Amgen Delivers Solid Q3 Sales, Little Insight On Key R&D Programs
Question Of Omecamtiv, Sotorasib Filing Plans Unanswered
Executive Summary
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
You may also be interested in...
J.P. Morgan Day 1: Companies Make Deal-Making, COVID-19 Promises
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Business development is key topic for Amgen and Vertex; BioNTech talks COVID-19 vaccine supply while Merck KGAA's new CEO pledges to rise to meet the challenges posed by COVID-19.
J.P. Morgan Day 1: Companies Make Deal-Making, COVID-19 Promises
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Business development is key topic for Amgen and Vertex; BioNTech talks COVID-19 vaccine supply while Merck KGAA's new CEO pledges to rise to meet the challenges posed by COVID-19.
Amgen’s Otezla And BMS’s Sotyktu Battle For Share In Oral Psoriasis Drug Market
Amgen and Bristol defended their positions in the post-topical/pre-biologic segment of the psoriasis market during their Q4 earnings calls, now that each company has an oral drug available.